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Abstract There is a positive association between sulfatide
and atherosclerosis in an animal model for human familial
hypercholesterolemia. Carotid intima–media thickness (IMT)
is thought to be a marker of atherosclerosis in humans. We
investigated the relationship between sulfatide and carotid
IMT in heterozygous familial hypercholesterolemia (FH) pa-
tients. Thirty-five genetically-verified heterozygous patients
with FH and 34 healthy controls were recruited into our study.
We measured serum sulfatide levels, the carotid IMT, and
conventional cardiovascular risk factors including obesity
parameters, blood pressure, fasting blood glucose, and lipid
profiles. Subjects with heterozygous FH had significantly
elevated serum sulfatide, elevated total cholesterol, low-
density lipoprotein cholesterol, and increased carotid IMT
compared with control subjects. In patients with FH,
univariate analysis showed that serum sulfatide was
significantly correlated with carotid IMT. Multiple linear
regression analysis indicated that serum sulfatide was
the only independent predictor of carotid IMT in pa-
tients with FH. Patients with heterozygous FH had signifi-
cantly higher carotid IMTand the level of serum sulfatide was
independently associated with atherosclerotic progression.
(R: 0.720, R2: 0.503, p<0.001).
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Introduction
Sulfatides are esters of sulfuric acid with galactosylceramides
at C3 of the galactosyl residue, that are widely distributed in
various animal organs and sera, including humans [1]. Over
the last two decades, Hara, et al. have been continuously
reporting the possible involvement of sulfatides in the cardio-
vascular system. First, using an animal model for human FH-
WHHL (Watanabe hereditable hyperlipidemic) rabbits, they
did a series of experiments comparing normal and WHHL
rabbi ts , and revealed that sulfat ides , the major
glycosphingolipids in serum lipoproteins, are markedly ele-
vated in WHHL rabbits [2] and accumulated in atheromatous
plaques in the aortae of WHHL rabbits [3], which suggested
sulfatides maybe take part in the progress of atherosclerosis,
even CVD (cardiovascular disease). We subsequently found a
close correlation between low levels of serum sulfatides and a
high risk of CVD in patients with end-stage renal failure. The
findings suggested that sulfatides maybe a novel biomarker
predicting the incidence of CVD in patients with end-stage
renal failure [4]. We also found that sulfatides were associated
with neointimal thickening after vascular injury [5]. In addi-
tion, it has been reported that exogenous sulfatide could cause
the development of intimal hyperplasia [6]. Therefore,
sulfatides may be possibly associated with atherosclerosis in
humans.
Carotid intima–media thickness (IMT) measured by high-
resolution ultrasonography is thought to be a marker of ath-
erosclerosis that is associated with future cardiovascular
events [7, 8].
In this study, we investigated the association between
sulfatide levels and carotid IMT in FH subjects who had no
major cardiovascular risk factors except hypercholesterol-
emia, in order to confirm the possible association between
sulfatides and atherosclerosis.
G. Li (*)




Clinical Laboratory, The Second Hospital of Hebei Medical
University, Shijiazhuang, Hebei, China




We recruited 35 patients with low density lipoprotein choles-
terol (LDL-C) >4.92 mmol/l and positive family history of
hypercholesterolemia in a genetic screening program for FH
in Shijiazhuang, China, from October 2008 to November
2010. Charng’s methodology was used in the subjects for
mutation detection of FH [9]. Other secondary causes of
hypercholesterolemia were excluded, including nephrotic
syndrome, liver disease, hypothyroidism, and diabetes
mellitus. We also recruited 34 healthy people as the
control group. These healthy individual’s LDL-C levels
were less than 3.37 mmol/l and their family members
were genetically verified as not carrying an FH-related
mutation allele.
This study was conducted in accordance with the
Declaration of Helsinki. Signed informed consent was obtain-
ed from all of the subjects, and the Medical Ethics Committee
of the HeBei General Hospital approved the study protocols.
Clinical characteristics and biochemical analysis
By a standardized questionnaire, trained nurses interviewed
all participants and obtained their medical history. Participants
rested for 10 min prior to their blood pressure being checked
twice at an interval of at least 1 min. The mean value of these
two measurements was used for the analyses. Each participant
was clothed only in a light gown and their weight and height
were measured. We calculated their body mass index as body
weight (kg) divided by the square of height (m2).
Subsequently, the same examiner measured waist circumfer-
ence between the lowest rib and the iliac crest in a standing
position.
All medications that could affect lipid levels were
discontinued 1month previous to the study. After an overnight
fast of 12 to 14 h, blood samples were obtained from all
subjects early in the morning. Total cholesterol, high-density
lipoprotein (HDL) cholesterol, triglyceride levels, and the
low-density lipoprotein (LDL) cholesterol level in blood sam-
ples were measured by an autobiochemical analysis system
(AU2700, Olympus, Japan). The concentrations of apolipo-
protein A1 and apolipoprotein B were measured by nephe-
lometry (Behring Diagnostic, Marburg, Germany). The
cholesterol-year score was calculated with the following equa-
tion: cholesterol-year score = yearly mean cholesterol serum
level × age. For the measurement of the sulfatides, the serum
was stored at −80 °C until analyzed.
Measurement of serum sulfatide
Sulfatides were extracted from specimens using a hexane–
isopropanol mixture and analyzed as lyso-forms (sulfatides
without fatty acids) using a high-throughput method devel-
oped in our laboratory [10]. Briefly, the total lipids were
extracted from 50 μl of serum with n-hexane: isopropanol
(3:2, v/v). After dried and hydrolyzed with 0.1 N NaOH in
90 % methanol at 150 °C for 30 min, sulfatides were convert-
ed to lyso-sulfatides. Subsequently, samples were desalted by
Mono-tip C18 tips (GL Sciences, Tokyo, Japan) and analyzed
by matrix-assisted laser desorption ionization time-of-flight
Table 1 Baseline and clinical
data of controls and individuals
with familial
hypercholesterolemia
NS Not significant; BMI Body
mass index; SBP Systolic blood
pressure; DBP Diastolic blood
pressure; HDL-C High density
lipoprotein- cholesterol; LDL-C
Low-density lipoprotein- choles-
terol; IMT Intima media thickness
Control (n=34) Familial hypercholesterol
subjects (n=35)
Significance
Age (years) 48.1±11.6 48.4±11.3 NS
Gender (male)(%) 50.0 48.6 NS
BMI (kg/m2) 24.2±1.8 24.7±1.7 NS
Waist circumference (cm) 85.0±5.4 83.8±5.2 NS
Waist-hip ratio 0.86±0.04 0.86±0.04 NS
SBP (mmHg) 130±14 136±12 NS
DBP (mmHg) 79±12 82±10 NS
Fasting blood glucose (mmol/l) 5.7±0.9 5.4±0.6 NS
Total cholesterol (mmol/l) 5.1±0.6 7.9±1.2 <0.001
Triglyceride (mmol/l) 1.4±0.5 1.5±0.5 NS
HDL-C (mmol/l) 1.3±0.3 1.3±0.3 NS
LDL-C (mmol/l) 3.1±0.7 5.5±1.0 <0.001
Cholesterol-year score (mmol-y/l) 247.1±71.8 381.8±105.9 <0.001
Apolipoprotein B (g/l) 1.0±0.2 1.4±0.3 <0.001
Apolipoprotein A1 (g/l) 1.3±0.1 1.3±0.1 NS
Serum sulfatide (μmol/l) 8.14±2.68 11.30±3.91 <0.001
Carotid IMT (mm) 0.77±0.13 1.22±0.52 <0.001
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mass spectrometry with delayed ion extraction using a
Voyager Elite XL Biospectrometry Workstation (PerSeptive
Biosystems, Framingham, MA, USA). A nitrogen laser
(337 nm) was used for ionization and negative ion mode
detection was employed.
Measurement of carotid intima–media thickness
The carotid arteries were evaluated by a single operator, blind
to subject details with a high-resolution B-mode ultrasonog-
raphy instrument using a 7.5 MHz probe (SSA-270A;
Toshiba, Tokyo, Japan). Participants were scanned in the
supine position with the neck hyperextended. Both common
carotid arteries were thoroughly scanned from proximal to
distal to the bifurcation. Frozen photocopies of end-
diastolic images in the longitudinal view showed the
bifurcation were captured. All images were taken when
the inner echoes of both near and far wall were clearly
visible. The IMT was measured at the far wall of both of the
common carotid arteries about 1 cm proximal to the carotid
bulb and defined as the mean of the maximal IMT of each
common carotid artery.
Statistical analysis
Results are shown by means and standard deviations (SDs)
for continuous variables and proportions for categorical vari-
ables. T-tests were used in between-group comparisons. In FH
subjects, Spearman’s correlation coefficients were determined
to assess the association between continuous carotid IMT,
conventional plasma lipids and lipoproteins, blood pressure
values, and serum sulfatide levels. In order to test whether
these variables had independent effects on the carotid IMT of
FH subjects, a stepwisemultiple linear regression analysis was
performed and the predictors for carotid IMT were
determined.
The SPSS 13.0 program (SPSS Inc., Chicago, IL, USA)
was used to perform all statistical analyses. All tests were 2-
sided and a value of p<0.05 was considered statistically
significant.
Results
The baseline characteristics of the study subjects are presented
in Table 1. The subjects with either a history of cardiovascular
disease, hypertension, or diabetes mellitus were excluded in
our study. Five of the FH subjects and three of the control
subjects were current smokers. Compared with the control
Fig. 1 a Graph shows correlation between cholesterol-year score and
carotid IMT (r=0.389, p<0.05). b Graph shows correlation between
serum sulfatide and carotid IMT (r=0.838, p<0.001)
Table 2 Spearman’s correlation coefficients for risk factors in individ-




r P value r P value
Age 0.436 <0.001 0.402 <0.001
Sex −0.031 NS −0.056 NS
BMI 0.632 <0.05 0.695 <0.05
Waist circumference 0.600 <0.05 0.725 <0.05
Waist-hip ratio 0.678 <0.05 0.726 <0.05
SBP 0.401 <0.05 0.505 <0.05
DBP 0.412 <0.05 0.591 <0.05
Fasting blood glucose 0.418 NS 0.414 NS
Total cholesterol 0.281 NS 0.216 NS
Triglyceride 0.512 <0.05 0.101 <0.05
HDL-C −0.181 NS −0.116 NS
LDL-C 0.284 NS 0.316 NS
Cholesterol-year score 0.526 <0.001 0.407 <0.001
Apolipoprotein B 0.384 <0.05 0.516 <0.05
Apolipoprotein A1 0.054 NS 0.026 NS
Serum sulfatide 0.600 <0.001 – –
NS Not significant; BMI Body mass index; SBP Systolic blood pressure;
DBPDiastolic blood pressure;HDL-CHigh density lipoprotein- cholester-
ol; LDL-C Low-density lipoprotein- cholesterol
Glycoconj J (2014) 31:587–592 589
group, FH subjects had significantly elevated serum levels of
total cholesterol, LDL cholesterol, and apolipoprotein B. In
addition, the cholesterol-year score, serum sulfatide levels,
and carotid IMT in FH subjects, were significantly higher than
those of the control subjects (Table 1). As we all known, the
calculated cholesterol-year score is often thought a marker of
total cholesterol burden, and carotid IMT is often thought a
marker of systemic atherosclerosis. In our study, as shown in
Fig. 1a, the cholesterol-year score was positively correlated
with the carotid IMT (r=0.389, p<0.05), which is consistent
with the findings in a previous study [11]. In addition, the
serum sulfatide levels were also positively correlated with the
carotid IMT (r=0.838, p<0.001) (Fig. 1b). The correlation
between serum sulfatide levels and carotid IMT seems to be
closer than the correlation between cholesterol-year score and
carotid IMT.
Table 2 showed that the carotid IMT was significantly
correlated with age, body mass index, waist circumference,
waist-hip ratio, systolic and diastolic blood pressures, triglyc-
eride levels, apolipoprotein B levels, the cholesterol-year
score, and serum sulfatide level. In addition, the serum
sulfatide level was also associated with age, body mass index,
waist circumference, waist-hip ratio, systolic and diastolic
blood pressures, triglyceride levels, apolipoprotein B levels,
and the cholesterol-year score.
We further divided FH subjects into 2 groups according to
the extent of carotid IMT (cut-off value: 1 mm). Listed in
Table 3, FH subjects with a carotid IMT > 1 mm were older.
The bodymass index, waist circumference, triglyceride levels,
and the cholesterol-year score in FH subjects with a carotid
IMT > 1 mm were higher than those in FH subjects with IMT
≤ 1 mm. In addition, the serum sulfatide level in FH subjects
with a carotid IMT > 1 mm was significantly higher than that
in FH subjects with IMT ≤ 1 mm. In order to clarify the
correlation of serum sulfatide and carotid IMT, we performed
stepwise multiple linear regression analyses for serum
sulfatide and carotid IMT, adjusted for age, gender, body mass
index, waist circumference, systolic and diastolic blood pres-
sures, triglyceride levels, apolipoprotein B levels, fasting
blood glucose, and the cholesterol-year score. The results
showed that the serum sulfatide level was an independent
predictor for the extent of carotid IMT (Partial R: 0.720, R2:
0.503, p<0.001).
Discussion
The carotid intima media thickness is a good surrogate marker
for atherosclerosis and is commonly used to measure the
extent of atherosclerosis [12, 13]. In this study, we have found
that serum sulfatide level is significantly and independently
associated with increased IMT in familial hypercholesterol-
emia patients, even after controlling for other atherosclerosis
risk factors. Therefore, serum sulfatide may be a novel risk
factor for atherosclerosis.
As we all know, low-grade inflammation has been impli-
cated in the progression of atherosclerosis [14]. One previous
study has demonstrated a role for sulfatide in atherogenesis
and vascular inflammation [5].
Firstly, sulfatide exists in serum lipoprotein of various
mammals including humans [10]. Studies revealed that the
increased sulfatide in both lipoprotein and atherosclerotic
plaques in WHHL rabbits- an animal model for human FH,
is intimately correlated with the development of
Table 3 Basic characteristics in
individuals with familial
hypercholesterolemia grouped by
carotid intima media thickness
NS Not significant; BMI Body
mass index; SBP Systolic blood
pressure; DBP Diastolic blood
pressure; HDL-C High density
lipoprotein- cholesterol; LDL-C
Low-density lipoprotein- choles-
terol; IMT Intima media thickness
Carotid intima media
thickness ≤1 mm (n=17)
Carotid intima media
thickness >1 mm (n=18)
Significance
Age (years) 41.8±11.6 54.6±14.2 <0.05
Gender (male)(%) 47.8 49.1 NS
BMI (kg/m2) 23.6±3.1 25.7±2.6 <0.05
Waist circumference (cm) 81.4±6.0 86.0±7.3 <0.05
SBP (mmHg) 136±13 136±11 NS
DBP (mmHg) 84±12 81±8 NS
Fasting blood glucose (mmol/l) 5.4±0.5 5.4±0.6 NS
Total cholesterol (mmol/l) 7.8±1.3 7.9±1.2 NS
Triglyceride (mmol/l) 1.3±0.4 1.7±0.6 <0.05
HDL-C (mmol/l) 1.2±0.2 1.3±0.3 NS
LDL-C (mmol/l) 5.6±0.9 5.4±1.1 NS
Cholesterol-year score (mmol-y/l) 325.5±94.8 437.7±148.5 <0.05
Apolipoprotein B (g/l) 1.3±0.3 1.4±0.3 NS
Apolipoprotein A1 (g/l) 1.3±0.2 1.3±0.1 NS
Serum sulfatide (μmol/l) 9.08±2.57 13.40±3.96 <0.001
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atherosclerosis: in serum lipoproteins of WHHL rabbits,
sulfatide content (121 nmol/ml serum) is markedly increased
by 40-fold over the normal level, while phospholipid content
is about 7 times the normal level due to hyperlipidemia. The
level of sulfatide is sufficiently high to prolong the fibrin-
precipitation time to twice the normal level and the enrichment
of sulfatide in serum lipoprotein is correlated to the self-
protecting effect against thrombosis by prolongation of the
blood-coagulation time. Furthermore, lipid analysis of athero-
sclerotic aortae ofWHHL rabbits revealed that a large amount
of sulfatide was accumulated there, while normal aorta
contained no sulfatide at all [2, 3]. We also found that a large
proportion of all serum sulfatide is derived from the liver and
that the remainder is derived from the small intestine [15].
Redundant circulating sulfatides synthesized in the liver and
small intestine may be accumulated in atherosclerotic plaques
in FH.
Secondly, sulfatide was demonstrated to play an important
physiological role in the vascular inflammation associated
with the development of atherothrombosis or atherosclerosis
[14]. In the vascular inflammatory process, activation of leu-
kocytes, neutrophils as well as monocytes, and their interac-
tions with platelets are mediated by cell adhesion molecules.
The cross talk of leukocyte integrin Mac-1 (CD11b/CD18)
and platelet membrane surface P-selectin is known to play an
especially important role [16, 17]. The activation and up-
regulation of Mac-1 on the surface of neutrophils and an
increase in the expression of P-selectin on the surface of
platelets were associated with the increased vascular wall
thickness [18]. Sulfatides are known to be a native ligand of
P-selectin and could interact with multiple cell adhesion mol-
ecules [19]. Sulfatides are also expressed on the membrane
surface of, and excreted by, neutrophils [20]. Since neutrophil
activation occurred after vascular inflammation [21],
sulfatides released from activated neutrophils may also act
agonistically as a P-selectin ligand and promote P-
selectin-Mac-1 cross talk, resulting in the activation of
Mac-1 (i.e., the reactivation of neutrophils), subsequent-
ly, resulting in vascular wall thickness and lumen loss
[18, 21].
Thirdly, we should point out some of the limitations of our
study: the relatively small sample size could not reflect the
association between serum sulfatide and carotid IMT in hu-
man FH completely.
At last, we showed serum sulfatide levels are significantly
associated with increased carotid IMT, namely with the prog-
ress of atherosclerosis, in FH patients. Therefore, the sulfatide-
dependent pathway would be a novel target for prevention
and/or treatment of atherosclerosis.
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